Kanghua Biotech announced that the company held an extraordinary shareholders' meeting on April 29, 2026 to review and pass on the foreign investment and related transactions bill. It plans to purchase Namixin's additional registered capital and transfer shares in installments. After the transaction is completed, it will hold 100% of Namixin's shares. Recently, Namixin completed the industrial and commercial change registration procedures for the first phase of this transaction and obtained a “Business License” issued by the China Pilot Free Trade Zone Market Supervision Administration, with a registered capital of RMB 27.17 million. The company will promptly fulfill its obligation to disclose information in accordance with subsequent developments.

Kanghua Biotech announced that the company held an extraordinary shareholders' meeting on April 29, 2026 to review and pass on the foreign investment and related transactions bill. It plans to purchase Namixin's additional registered capital and transfer shares in installments. After the transaction is completed, it will hold 100% of Namixin's shares. Recently, Namixin completed the industrial and commercial change registration procedures for the first phase of this transaction and obtained a “Business License” issued by the China Pilot Free Trade Zone Market Supervision Administration, with a registered capital of RMB 27.17 million. The company will promptly fulfill its obligation to disclose information in accordance with subsequent developments.